For example, clinical success has been observed with the ERBB2 antibody trastuzumab (Herceptin) in the treatment of ERBB2-amplified breast cancer (108), crizotinib in the treatment of MET-amplified non-small cell lung cancer (109), and the epidermal growth factor receptor (EGFR) inhibitors gefitinib and erlotinib (which blocks the catalytic activity of EGFR) in lung cancer patients with EGFR mutations (110). Here, ERBB2 is linked to non-small cell lung carcinoma.